NCT03727152View on ClinicalTrials.gov

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
HIV
Interventions
DRUG

generic single tablet TAF/FTC/DTG

HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir

Trial Locations (2)

10330

HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok

Police General Hospital, Bangkok

All Listed Sponsors
collaborator

Faculty of Medical Sciences, Radboud University of Medical Center

UNKNOWN

collaborator

Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University

UNKNOWN

collaborator

Police General Hospital

OTHER

lead

The HIV Netherlands Australia Thailand Research Collaboration

OTHER

NCT03727152 - Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir | Biotech Hunter | Biotech Hunter